Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relmacabtagene autoleucel + tislelizumab
- Development stage
- Preclinical
- Lead developer
- JW Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of relmacabtagene autoleucel (relma-cel), a CD19-targeted CAR-T cell therapy, and tislelizumab, a PD-1 inhibitor. This combination has shown promising efficacy in treating relapsed/refractory large B-cell lymphoma (LBCL) and central nervous system lymphoma (CNSL). The therapy works through dual mechanisms: relma-cel targets CD19-expressing cancer cells while tislelizumab prevents T-cell exhaustion by blocking the PD-1 pathway, leading to significant re-expansion of CAR T-cells after administration.
- Brand names
- Carteyva + tislelizumab
- Other names
- relma-cel + tislelizumab
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on relmacabtagene autoleucel + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relmacabtagene autoleucel + tislelizumab.